S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The single greatest medical breakthrough of all time? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The single greatest medical breakthrough of all time? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The single greatest medical breakthrough of all time? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The single greatest medical breakthrough of all time? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NYSE:QGEN

Qiagen - QGEN Stock Forecast, Price & News

$50.46
+0.92 (+1.86%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$49.82
$50.49
50-Day Range
$41.93
$50.46
52-Week Range
$40.38
$56.18
Volume
595,533 shs
Average Volume
933,117 shs
Market Capitalization
$11.46 billion
P/E Ratio
25.10
Dividend Yield
N/A
Price Target
$56.53

Qiagen MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
12.0% Upside
$56.53 Price Target
Short Interest
Bearish
2.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.40mentions of Qiagen in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-9.48%
From $2.32 to $2.10 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

872nd out of 1,047 stocks

Biological Products, Except Diagnostic Industry

148th out of 173 stocks

QGEN stock logo

About Qiagen (NYSE:QGEN) Stock

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Stock News Headlines

Brokerages Set Qiagen (NYSE:QGEN) Price Target at $54.65
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio
QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
See More Headlines
Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Company Calendar

Last Earnings
11/07/2022
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/14/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Employees
6,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$56.53
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$54.60
Forecasted Upside/Downside
+12.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$512.60 million
Pretax Margin
25.70%

Debt

Sales & Book Value

Annual Sales
$2.25 billion
Cash Flow
$3.90 per share
Book Value
$14.65 per share

Miscellaneous

Free Float
206,637,000
Market Cap
$11.46 billion
Optionable
Optionable
Beta
0.38

Key Executives

  • Mr. Thierry Bernard (Age 57)
    CEO, MD & Member of Management Board
    Comp: $2.02M
  • Dr. Roland Sackers (Age 53)
    CFO, MD & Member of Management Board
    Comp: $1.18M
  • Mr. Antonio Santos
    Sr. VP & Head of Global Operations
  • Mr. John Gilardi
    VP of Corp. Communications & Investor Relations
  • Ms. Stephany Foster
    Sr. VP & Head of HR
  • Dr. Thomas Schweins
    Sr. VP of Life Science Bus. Area
  • Dr. Thomas Theuringer
    Sr. Director & Head of External Communications
  • Mr. Jean-Pascal Viola
    Sr. VP & Head of Molecular Diagnostics Bus. Area
  • Dr. Jonathan G. Sheldon Ph.D. (Age 50)
    Sr. VP of Qiagen Digital Insights Bus. Area
  • Mr. Thomas Neidert
    VP of Global Treasury













QGEN Stock - Frequently Asked Questions

Should I buy or sell Qiagen stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" QGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QGEN, but not buy additional shares or sell existing shares.
View QGEN analyst ratings
or view top-rated stocks.

What is Qiagen's stock price forecast for 2023?

6 brokerages have issued 12-month price objectives for Qiagen's stock. Their QGEN share price forecasts range from $54.60 to $60.00. On average, they anticipate the company's stock price to reach $56.53 in the next twelve months. This suggests a possible upside of 12.0% from the stock's current price.
View analysts price targets for QGEN
or view top-rated stocks among Wall Street analysts.

How have QGEN shares performed in 2022?

Qiagen's stock was trading at $55.58 on January 1st, 2022. Since then, QGEN stock has decreased by 9.2% and is now trading at $50.46.
View the best growth stocks for 2022 here
.

When is Qiagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our QGEN earnings forecast
.

How were Qiagen's earnings last quarter?

Qiagen (NYSE:QGEN) released its quarterly earnings data on Monday, November, 7th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.45 by $0.08. The firm earned $499.63 million during the quarter, compared to the consensus estimate of $479.99 million. Qiagen had a net margin of 20.83% and a trailing twelve-month return on equity of 18.43%.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its FY 2022 earnings guidance on Monday, November, 21st. The company provided earnings per share (EPS) guidance of $2.40-$2.40 for the period, compared to the consensus EPS estimate of $2.21. The company issued revenue guidance of $2.25 billion-$2.25 billion, compared to the consensus revenue estimate of $2.13 billion.

What is Thierry Bernard's approval rating as Qiagen's CEO?

33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Who are Qiagen's major shareholders?

Qiagen's stock is owned by many different institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (9.02%), Vanguard Group Inc. (3.64%), BlackRock Inc. (3.24%), Pendal Group Ltd (2.32%), Marshall Wace LLP (1.04%) and State Street Corp (0.99%).

How do I buy shares of Qiagen?

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $50.46.

How much money does Qiagen make?

Qiagen (NYSE:QGEN) has a market capitalization of $11.46 billion and generates $2.25 billion in revenue each year. The company earns $512.60 million in net income (profit) each year or $2.01 on an earnings per share basis.

How many employees does Qiagen have?

The company employs 6,000 workers across the globe.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The official website for the company is www.qiagen.com. The company can be reached via phone at (177) 355-6600, via email at ir@qiagen.com, or via fax at 31-77-355-6658.

This page (NYSE:QGEN) was last updated on 12/2/2022 by MarketBeat.com Staff